Shatz & Brott

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

Synaptic Loss in Alzheimer's Disease: Evaluation of the C4d-LilrB2 Axis

Abstract

Cognitive decline in Alzheimer's disease (AD) correlates most strongly with loss of excitatory synapses in the hippocampus, neocortex, and entorhinal cortex—more robustly than with fibrillar amyloid plaque burden or neurofibrillary tangle load. Recent research by Barbara K. Brott, Carla J. Shatz, and colleagues identifies the complement cleavage product C4d as a high-affinity ligand for the neuronal receptor Leukocyte immunoglobulin-like receptor subfamily B member 2 (LilrB2), and its murine ortholog, Paired immunoglobulin-like receptor B (PirB). This analysis evaluates the biochemical, biophysical, and spatial evidence for C4d-LilrB2 binding and traces the downstream cofilin-actin signaling cascade that leads to dendritic spine collapse. The work integrates human genomic, fluid biomarker, and functional data to assess the mechanism's relevance to neurodegeneration. While the C4d-LilrB2 pathway provides a coherent mechanistic account of complement-mediated synaptic loss, critical questions remain about its relative contribution to overall AD pathology, the determinants of synapse-specific vulnerability, and the therapeutic efficacy of pathway antagonism in human patients.

Introduction

Alzheimer's disease represents a major global health burden, with dementia prevalence projected to rise substantially by mid-century¹. Despite decades of investigation and billions in pharmaceutical investment, only modestly effective disease-modifying therapies exist².

The Amyloid Cascade Hypothesis and Its Limitations

For much of the modern research era, the Amyloid Cascade Hypothesis dominated AD research: fibrillar amyloid-beta (Aβ) accumulates, triggering tau hyperphosphorylation⁴, neuronal death, and cognitive decline⁴. However, several observations have complicated this model:

• Up to 44% of cognitively normal older adults possess amyloid burdens equivalent to those in advanced AD⁵
• Individuals with minimal plaque pathology can exhibit severe dementia if synaptic loss is prominent⁵
• Modern neuropathological analysis consistently shows that synaptic density, not plaque burden, predicts cognitive status⁶ This evidence has shifted focus toward understanding the specific mechanisms targeting synapses for destruction.

Complement-Mediated Pruning and Neuronal Receptors

Two partly separate research directions emerged:

1. Microglial Engulfment (External Mechanism): The classical complement cascade—specifically the C1q-C3-CR3 axis—is upregulated in AD brains⁷ and recruits resident microglia to engulf synapses. Soluble Aβ oligomers activate C1q, initiating this cascade.
2. Neuronal Receptor Signaling (Internal Mechanism): The Shatz laboratory identified PirB (and its human ortholog LilrB2)—an MHC Class I receptor—as highly expressed on CNS pyramidal neurons²⁷. In 2013, they demonstrated that PirB/LilrB2 binds soluble Aβ oligomers with high affinity, triggering cofilin hyperactivation and dendritic spine collapse¹⁵. Genetic deletion of PirB in AD transgenic mice rescued synaptic plasticity and memory deficits.

The Unifying Discovery: C4d as a LilrB2 Ligand

The 2025 PNAS publication by Brott, Shatz, and colleagues provides evidence that C4d—a terminal cleavage product of complement C4—acts as a high-affinity ligand for LilrB2/PirB¹⁶. This finding potentially unifies external and internal mechanisms: the same complement cascade that tags synapses for microglial removal also generates a signal that instructs neurons to dismantle their own dendritic spines.

Analytical Framework

Evaluating these claims requires integration of:

• High-Resolution Spatial Validation: Array Tomography (AT)³⁸ permits precise colocalization of LilrB2, C4d, and Aβ at individual synapses without the z-axis blurring of standard microscopy
• Biophysical Kinetics: Surface Plasmon Resonance (SPR) quantifies binding affinity (dissociation constants); mutant domain analysis maps binding sites
• In Vivo Functional Validation: Osmotic minipump infusions of C4d into mouse cortex, combined with PirB-knockout controls, test causality
• Human Genomics: Genome-Wide Association Studies and cerebrospinal fluid proteomics establish clinical relevance

Chapter 1: The Molecular Architecture of the C4d-LilrB2 Axis

Complement Cascade Basics

The classical complement pathway is initiated by the C1 complex. Upon activation, C1s protease cleaves C4 into C4a (soluble) and C4b (membrane-tetherable). Factor I subsequently cleaves membrane-bound C4b into C4c and C4d; C4d remains covalently attached to the original surface.

C4d as a Previously "Orphan" Ligand

Historically, C4d has been viewed as a stable byproduct of complement activation—a clinical biomarker for antibody-mediated rejection or autoimmune activity⁴⁶. It lacked an identified physiological receptor or known CNS signaling function.

The C4d-LilrB2 Interaction

The Brott-Shatz study identified LilrB2 as the receptor for C4d through:

• Dot blot analysis: LilrB2 (as an Fc-tagged extracellular domain) binds C4d intensely but shows negligible affinity for C4, C4a, or C4b
• Surface Plasmon Resonance: C4d binds LilrB2 with a dissociation constant (Kd) of ~3 nM (cell-free), 37 nM (HEK293 cells), 56 nM (murine PirB), and 380 nM (primary neuronal cultures)—all consistent with high-affinity binding
• Domain Mapping: Using truncated Fc-tagged mutants, binding maps to the N-terminal D1D2 immunoglobulin domains—the same domains that bind Aβ oligomers and MHC Class I This makes LilrB2 a convergence receptor: it integrates signals from pathogenic protein aggregates (Aβ), neuroinflammation (C4d), and developmental/immune status (MHC-I).

Spatial Colocalization at Human Synapses

Using Array Tomography on post-mortem tissue from temporal and prefrontal cortices:

• In normal tissue, LilrB2 overlaps with C4d puncta in the neuropil
• Approximately 60% of excitatory synapses (identified by VGlut1/PSD95) show colocalized C4 or LilrB2 signal; ~30% contain explicit C4d
• In AD brains, C4d-LilrB2 colocalization is enriched near amyloid plaques
• Oligomeric Aβ, LilrB2, and C4d are frequently detected together at individual synapses showing signs of distress This spatial evidence places the molecular machinery at sites of maximal pathology and cognitive decline.

Chapter 2: Signal Transduction and Structural Collapse

Actin Dynamics and Cofilin

Dendritic spine architecture depends on a dynamic network of filamentous actin (F-actin). Cofilin—an actin-severing protein—regulates this balance:

• Phosphorylated cofilin (inactive): F-actin networks remain stable; the spine maintains structural integrity¹⁷
• Dephosphorylated cofilin (active): Severing F-actin monomers increases structural fluidity; brief activation supports normal synaptic plasticity The balance is maintained by kinases (e.g., LIMK) that phosphorylate cofilin and phosphatases (e.g., Slingshot/SSH1) that dephosphorylate it.

Pathological Hyperactivation

Upon binding of Aβ oligomers or C4d to LilrB2/PirB, intracellular signaling recruits phosphatases via the receptor's immunoreceptor tyrosine-based inhibitory motifs (ITIMs)⁵², driving massive cofilin dephosphorylation. At pathologically elevated concentrations, active cofilin shifts from severing to bundling F-actin, forming rigid, insoluble cofilin-actin rods. These rods:

• Occlude the dendritic spine neck¹¹
• Disrupt intracellular vesicular trafficking
• Impede delivery of post-synaptic receptors (AMPA, NMDA) and mitochondria¹¹
• Lead to structural spine collapse and synaptic disconnection

In Vivo Functional Evidence

Osmotic minipump infusion of recombinant C4d into adult mouse primary visual cortex resulted in:

• Rapid, statistically significant decrease in dendritic spine density on basolateral dendrites of layer 5 pyramidal neurons in wild-type mice¹⁶
• Complete prevention of spine loss in PirB-knockout mice, with spine density indistinguishable from control BSA-infused animals¹⁶ This demonstrates that C4d is sufficient to drive structural pruning in living mammalian brain, and that PirB receptor is the necessary conduit for this effect.

Dual-Pathway Pruning Model

The convergent evidence suggests a unified mechanism:

1. External (Glial) Axis: C4b facilitates C3 cleavage into C3b/iC3b, which opsonizes the synapse and recruits CR3+ microglia for phagocytosis⁴⁸
2. Internal (Neuronal) Axis: C4d remains tethered and binds post-synaptic LilrB2, triggering cofilin hyperactivation and structural collapse¹⁶ These processes are synergistic: a synapse that is internally destabilized, functionally silent, and shrinking via the C4d-LilrB2-cofilin axis becomes a more attractive target for microglial engulfment. Targeting only the glial component (e.g., anti-C1q, anti-CR3) may be insufficient if neuronal structural collapse proceeds unchecked.

Chapter 3: Human Genetics, Biomarkers, and Clinical Relevance

Genome-Wide Association Studies

Recent large-scale GWAS (hundreds of thousands of participants) have identified over 75 AD risk loci¹⁹. Among the most significant novel findings is the LILRB2 locus.

Ethnic-Specific Effects: Genetic variation at LILRB2-LILRB5 shows opposite associations across

populations⁴². For example, a lead variant (rs587709-T) is associated with decreased AD risk and altered LILRB5 expression in European cohorts but increased AD risk and elevated LILRB2 expression in East Asian populations. This highlights the necessity of cross-ancestry genetic studies.

Convergence with Schizophrenia Genetics

The genetic locus encoding complement C4 shows strong associations with schizophrenia—a disorder characterized by aberrant synaptic pruning in the prefrontal cortex during late adolescence. The finding that C4d binds LilrB2 suggests a shared pathophysiological mechanism: regardless of whether the initial trigger is amyloid-driven (aging, AD) or C4 overexpression (schizophrenia), the terminal event may be C4d-LilrB2-mediated synapse elimination. This remains speculative and requires direct experimental validation.

C4d as a Fluid Biomarker

• Proteomic analysis of human brain tissue shows C4d is elevated ~4-fold in prefrontal cortex of AD patients versus cognitively normal controls¹⁶
• C4d possesses a robust plasma half-life⁴⁶ (unlike highly transient fragments C3a, C5a)
• Higher plasma C4d correlates with memory impairment, active amyloid PET accumulation, and accelerated progression from Mild Cognitive Impairment to dementia¹⁰
• C4d may provide a window into real-time neuroimmune activation intensity, facilitating earlier intervention and trial stratification Unknown: The specificity of C4d for AD-related pathology versus other neuroinflammatory conditions, and whether C4d levels are better predictors of cognitive decline than existing biomarkers.

Therapeutic Targeting

LilrB2 Antagonism

Monoclonal antibodies engineered to block the D1D2 domains of LilrB2 aim to:

• Shield synapses from both Aβ-driven and C4d-driven toxicity³
• Preserve dendritic spine integrity and cofilin-actin architecture

Microglial Disinhibition via TREM2

LilrB2 is heavily expressed on microglia⁶⁹, where it functions as an inhibitory immune receptor that suppresses activation. TREM2 is a beneficial sensor that activates microglia to phagocytose plaques and clear debris. Recent evidence indicates that LILRB2 acts as a molecular brake on TREM2 signaling⁶⁹. Consequently, a LILRB2-blocking antibody may achieve dual effects:

• Direct neuroprotection: Prevents neurotoxic signaling at the synapse
• Enhanced plaque clearance: By relieving ITIM-mediated inhibition on microglia, it hyperactivates beneficial TREM2 signaling and increases microglial phagocytosis⁴² Status: This mechanism is supported by preclinical evidence; clinical efficacy in human patients remains untested.

What This Analysis Cannot Determine

Outstanding Mechanistic Questions

1. Relative Contribution to Overall Pathology: What proportion of AD synaptic loss is attributable to the C4d-LilrB2 axis versus other complement fragments, Aβ receptors, or tau-related mechanisms? This cannot be determined from current evidence.
2. Synapse-Specific Vulnerability: Why do certain synapses within the same local microcircuit become targets for C4d-LilrB2 engagement while others are spared? The spatial proximity to plaques is documented, but the determinants of selective vulnerability remain unknown.
3. Threshold Effects and Kinetics: Is there a minimum C4d concentration required to trigger spine loss? What is the temporal lag between receptor engagement and structural collapse in intact tissue? These remain untested in human brain.
4. Interaction with Other Pathways: How do Aβ oligomers, tau, and C4d signaling interact at individual synapses? Do they compete, cooperate, or activate distinct populations of spines?

Translational Uncertainties

1. Clinical Efficacy of LilrB2 Antagonism: Preclinical evidence supports the mechanism, but Phase 1/2a clinical trials in human AD patients have not yet reported final efficacy endpoints. The safety profile in central nervous system pathology is unknown.
2. Biomarker Specificity: While C4d elevation correlates with AD pathology, specificity for AD-related mechanisms (versus, for example, microglial activation from infection, stroke, or other inflammatory conditions) is not established.
3. Ethnic-Specific Therapeutic Response: The opposing genetic associations at LILRB2 across populations suggest that antagonism may benefit some ancestry groups while potentially worsening disease in others. This critical question requires prospective, diversified clinical research.
4. Long-Term Safety of Complement Inhibition: Chronic inhibition of complement pathways—already implicated in healthy synaptic pruning during development and neural circuit refinement—could alter normal plasticity, learning capacity, or immune surveillance. Duration and reversibility of these effects are unknown.

Model Limitations

1. Species Translation: The primary experimental evidence derives from murine models and post-mortem human tissue. Acute C4d infusion in mouse cortex differs from chronic, system-wide complement dysregulation in aging human brain.
2. Cell-Type Specificity: While LilrB2 is expressed on neurons and microglia, contributions from glial cells, astrocytes, and other CNS cell types have not been fully characterized.
3. Genetic Background: AD transgenic mouse models may not recapitulate the full complexity of late-onset AD, where amyloid accumulation is often asymptomatic and multiple parallel pathologies contribute to decline.

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Conclusion

The identification of C4d as a high-affinity LilrB2 ligand provides a mechanistic account of how the complement cascade—a system evolved for pathogen opsonization—can drive pathological synapse elimination in AD. The evidence integrates structural biology, neuroanatomy, transcriptomics, and in vivo physiology. Spatial colocalization at vulnerable synapses, high-affinity binding kinetics, and functional rescue in PirB-knockout mice establish the C4d-LilrB2 axis as one contributory mechanism in AD pathogenesis. However, the scope of this mechanism's contribution to overall cognitive decline remains incompletely defined. The convergence of evidence from multiple disciplines is suggestive rather than definitive. Therapeutic antagonism of LilrB2 represents a rational next step, with dual benefits for synaptic preservation and microglial plaque clearance. But clinical efficacy, optimal patient selection, and long-term safety in human patients remain to be determined through rigorous prospective trials. The work of Brott and Shatz illuminates a specific molecular node—C4d-LilrB2-cofilin—in the neuroimmune cascade. It advances mechanistic understanding but does not resolve the fundamental paradox of AD: why some individuals accumulate pathology without cognitive decline, why some decline without pathology, and how to intervene safely and effectively in an aging system that depends on many of these same mechanisms for normal function.

Works Cited

1. D'Argenio V, Tomaiuolo R, Bargeri S, Sancesario G. Alzheimer's 2030: From Precision Genomics to Artificial Intelligence. Genes (Basel) 2026;17(2). DOI 10.3390/genes17020233.

2. Wu CK, Fuh JL. A 2025 update on treatment strategies for the Alzheimer's disease spectrum. J Chin Med Assoc 2025;88(7):495-502. DOI 10.1097/JCMA.0000000000001252.

3. Alzheimer's Disease Pipeline Insights and Analysis 2025 - DelveInsight, accessed March 23, 2026, https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight

4. Cao Q, Shin WS, Chan H, Vuong CK, Dubois B, Li B, et al.. Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat Chem 2018;10(12):1213-1221. DOI 10.1038/s41557-018-0147-z.

5. Beyond Amyloid: Rethinking the Foundations of Alzheimer’s Disease Pathogenesis and Therapy. aging and disease 2025. DOI 10.14336/AD.2025.01119.

6. Subramanian J. How Do Amyloid Pathology and Aberrant Neuronal Activity Disrupt Plasticity and Memory in Alzheimer's Disease?. Neuroscientist 2026;32(2):112-125. DOI 10.1177/10738584251414384.

7. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al.. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016;352(6286):712-716. DOI 10.1126/science.aad8373.

8. Rishton GM, Look GC, Ni Z, Zhang J, Wang Y, Huang Y, et al.. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease. ACS Medicinal Chemistry Letters 2021;12(9):1389-1395. DOI 10.1021/acsmedchemlett.1c00048.

9. Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/synaptic-neuroscience/articles/023.1129036

10. Papavergi MT, Bathini P, Singh B, Lemere CA. The complement cascade in Alzheimer's disease: modern implications of an ancient immune protagonist. Mol Neurodegener 2025;21(1):5. DOI 10.1186/s13024-025-00916-y.

11. Bamburg JR, Bernstein BW, Davis RC, Flynn KC, Goldsbury C, Jensen JR, et al.. ADF/Cofilin-actin rods in neurodegenerative diseases. Curr Alzheimer Res 2010;7(3):241-50. DOI 10.2174/156720510791050902.

12. Batista AF, Khan KA, Papavergi MT, Lemere CA. The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis. Int J Mol Sci 2024;25(2). DOI 10.3390/ijms25020817.

13. Gomez-Arboledas A, Acharya MM, Tenner AJ. The Role of Complement in Synaptic Pruning and Neurodegeneration. ImmunoTargets and Therapy 2021;Volume 10:373-386. DOI 10.2147/ITT.S305420.

14. Scientists reveal how beta-amyloid may cause Alzheimer's - Stanford Medicine, accessed March 23, 2026, https://med.stanford.edu/news/all-news/2013/09/scientists-reveal-how-beta-amyloid-may-cause-alzheimers.html

15. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, et al.. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013;341(6152):1399-404. DOI 10.1126/science.1242077.

16. Shatz, Brott_pnas.202519253.pdf

17. Brott BK, Raissi AJ, Micheva KD, Vielmetter J, Mendes MS, Baccus CJ, et al.. C4d, a high-affinity LilrB2 ligand, is elevated in Alzheimer’s disease and mediates synapse pruning. Proceedings of the National Academy of Sciences 2025;122(38). DOI 10.1073/pnas.2519253122.

18. Brott BK, Raissi AJ, Micheva KD, Vielmetter J, Mendes MS, Baccus CJ, et al.. C4d, a high-affinity LilrB2 ligand, is elevated in Alzheimer's disease and mediates synapse pruning. Proc Natl Acad Sci U S A 2025;122(38):e2519253122. DOI 10.1073/pnas.2519253122.

19. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al.. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 2022;54(4):412-436. DOI 10.1038/s41588-022-01024-z.

20. Scheff SW, Neltner JH, Nelson PT. Is synaptic loss a unique hallmark of Alzheimer's disease?. Biochem Pharmacol 2014;88(4):517-28. DOI 10.1016/j.bcp.2013.12.028.

21. Taddei RN, E Duff K. Synapse vulnerability and resilience underlying Alzheimer's disease. EBioMedicine 2025;112:105557. DOI 10.1016/j.ebiom.2025.105557.

22. Rethinking Alzheimer's: New Evidence Challenges a Long-Held Belief About Memory Loss, accessed March 23, 2026, https://scitechdaily.com/rethinking-alzheimers-new-evidence-challenges-a-long-held-belief-about-memory-loss/

23. Umunakwe O. Pathways from the Eye to the Brain. All about Your Eyes, Second Edition, revised and updated 2021:11-13. DOI 10.1515/9781478021209-018.

24. Aliakbari S, Asadi S, Sayyah M, Naderi N, Salarvandian S, Khodagholi F, et al.. Viral modulation of synaptic pruning: implications for neuropathology and brain function. J Virol 2026;100(2):e0168425. DOI 10.1128/jvi.01684-25.

25. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 2012;35:369-89. DOI 10.1146/annurev-neuro-061010-113810.

26. Lieberman OJ, McGuirt AF, Tang G, Sulzer D. Roles for neuronal and glial autophagy in synaptic pruning during development. Neurobiol Dis 2019;122:49-63. DOI 10.1016/j.nbd.2018.04.017.

27. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al.. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016;352(6286):712-716. DOI 10.1126/science.aad8373.

28. Foundational research on brain development may help prevent degeneration, accessed March 23, 2026, https://humsci.stanford.edu/feature/foundational-research-brain-development-may-help-prevent-degeneration

29. Immune system may target some brain synapses, Stanford researchers find, accessed March 23, 2026, https://med.stanford.edu/news/all-news/2007/12/immune-system-may-target-some-brain-synapses-stanford-researchers-find.html 31. (PDF) Human LilrB2 Is a -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/256837903_Human_LilrB2_Is_a_-Amyloid_Re ceptor_and_Its_Murine_Homolog_PirB_Regulates_Synaptic_Plasticity_in_an_Alzheimer's_Model

30. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, et al.. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013;341(6152):1399-404. DOI 10.1126/science.1242077.

31. Alzheimer's may trick the brain into erasing its own memories | ScienceDaily, accessed March 23, 2026, https://www.sciencedaily.com/releases/2026/01/260125083413.htm

32. Smith LM, Kostylev MA, Lee S, Strittmatter SM. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance. J Biol Chem 2019;294(15):6042-6053. DOI 10.1074/jbc.RA118.006252.

33. Smith LM, Kostylev MA, Lee S, Strittmatter SM. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance. J Biol Chem 2019;294(15):6042-6053. DOI 10.1074/jbc.RA118.006252.

34. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun 2021;12(1):3451. DOI 10.1038/s41467-021-23507-z.

35. Penke B, Szűcs M, Bogár F. Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis. Molecules 2020;25(7). DOI 10.3390/molecules25071659.

36. Bringing synapses into focus: Recent advances in synaptic imaging and mass-spectrometry for studying synaptopathy - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/synaptic-neuroscience/articles/023.1130198

37. Kay KR, Smith C, Wright AK, Serrano-Pozo A, Pooler AM, Koffie R, et al.. Studying synapses in human brain with array tomography and electron microscopy. Nat Protoc 2013;8(7):1366-80. DOI 10.1038/nprot.2013.078.

38. Array Tomography - iBiology, accessed March 23, 2026, https://www.ibiology.org/talks/array-tomography/

39. Carla Shatz | Stanford Medicine, accessed March 23, 2026, https://med.stanford.edu/profiles/carla-shatz

40. Cao H, Zheng Z, Zhou X, Kikuchi M, Wong HY, Cheng EYL, et al.. Ethnic-specific effects of the LILRB2-LILRB5 locus and newly identified risk loci for Alzheimer's disease in the East Asian population. Alzheimers Dement 2026;22(2):e71219. DOI 10.1002/alz.71219.

41. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al.. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 2022;54(4):412-436. DOI 10.1038/s41588-022-01024-z.

42. Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementia - medRxiv.org, accessed March 23, 2026, DOI 10.1101/2025.10.20.25338060">https://www.medrxiv.org/content/10.1101/2025.10.20.25338060

43. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al.. Author Correction: Schizophrenia risk from complex variation of complement component 4. Nature 2022;601(7892):E4-E5. DOI 10.1038/s41586-021-04202-x.

44. Cell-free DNA integrity and complement C4d as novel liquid biopsy biomarkers for paraneoplastic and non-paraneoplastic autoimmune encephalitis - Frontiers, accessed March 23, 2026, DOI 10.3389/fimmu.2025.1640532">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1640532

45. Jovčevska I, Videtič Paska A, Kouter K. Complement Cascades and Brain Disorders. Biomolecules 2025;15(8). DOI 10.3390/biom15081179.

46. Djurišić M. Immune receptors and aging brain. Biosci Rep 2024;44(2). DOI 10.1042/BSR20222267.

47. Shehjar F, Almarghalani DA, Mahajan R, Hasan SA, Shah ZA. The Multifaceted Role of Cofilin in Neurodegeneration and Stroke: Insights into Pathogenesis and Targeting as a Therapy. Cells 2024;13(2). DOI 10.3390/cells13020188.

48. Rush T, Martinez-Hernandez J, Dollmeyer M, Frandemiche ML, Borel E, Boisseau S, et al.. Synaptotoxicity in Alzheimer's Disease Involved a Dysregulation of Actin Cytoskeleton Dynamics through Cofilin 1 Phosphorylation. J Neurosci 2018;38(48):10349-10361. DOI 10.1523/JNEUROSCI.1409-18.2018.

49. Role of Cofilin in Alzheimer's Disease - Frontiers, accessed March 23, 2026, DOI 10.3389/fcell.2020.584898">https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.584898

50. Cazzaro S, Zhao X, Zhao VK, Kim YK, Woo JA. Slingshot homolog-1 amplifies mitochondrial abnormalities by distinctly impairing health and clearance of mitochondria. Hum Mol Genet 2023;32(10):1660-1672. DOI 10.1093/hmg/ddad006.

51. Woo JA, Zhao X, Khan H, Penn C, Wang X, Joly-Amado A, et al.. Slingshot-Cofilin activation mediates mitochondrial and synaptic dysfunction via Aβ ligation to β1-integrin conformers. Cell Death & Differentiation 2015;22(6):921-934. DOI 10.1038/cdd.2015.5.

52. Gasca-Martínez Y, Ontiveros-Torres MA, López-Gallegos I, Jarero-Basulto JJ. Amyloid Beta Oligomers as Early Triggers of Neuronal Cytoskeleton Dysfunction in Alzheimer's Disease. Pathophysiology 2026;33(1). DOI 10.3390/pathophysiology33010014.

53. Kuhn TB, Minamide LS, Tahtamouni LH, Alderfer SA, Walsh KP, Shaw AE, et al.. Chemokine Receptor Antagonists Prevent and Reverse Cofilin-Actin Rod Pathology and Protect Synapses in Cultured Rodent and Human iPSC-Derived Neurons. Biomedicines 2024;12(1). DOI 10.3390/biomedicines12010093.

54. Bamburg JR, Bernstein BW. Actin dynamics and cofilin-actin rods in alzheimer disease. Cytoskeleton (Hoboken) 2016;73(9):477-97. DOI 10.1002/cm.21282.

55. Djurisic M, Vidal GS, Mann M, Aharon A, Kim T, Ferrao Santos A, et al.. PirB regulates a structural substrate for cortical plasticity. Proc Natl Acad Sci U S A 2013;110(51):20771-6. DOI 10.1073/pnas.1321092110.

56. Tenner AJ, Stevens B, Woodruff TM. New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol Immunol 2018;102:3-13. DOI 10.1016/j.molimm.2018.06.264.

57. Ayyubova G, Fazal N. Beneficial versus Detrimental Effects of Complement-Microglial Interactions in Alzheimer's Disease. Brain Sci 2024;14(5). DOI 10.3390/brainsci14050434.

58. Massive GWAS Meta-Analysis Digs Up Trove of Alzheimer's Genes - Alzforum, accessed March 23, 2026, https://www.alzforum.org/news/research-news/massive-gwas-meta-analysis-digs-trove-alzheimers-genes

    Find this paper

59. New risk genes associated with Alzheimer's disease identified - VJDementia, accessed March 23, 2026, https://www.vjdementia.com/new-risk-genes-associated-with-alzheimers-disease-identified/

60. Loi KJ, Radtke N, Kiriluk C, Noureldein MH, Feldman EL, Bakulski KM, et al.. Shared genes and pathways in dementia: Insights from genome-wide association studies. Alzheimers Dement 2025;21(11):e70845. DOI 10.1002/alz.70845.

61. Interpretation of 10 years of Alzheimer's disease genetic findings in the perspective of statistical heterogeneity - Oxford Academic, accessed March 23, 2026, https://academic.oup.com/bib/article-pdf/doi/

    Find this paper

62. Cao H, Zheng Z, Zhou X, Kikuchi M, Wong HY, Cheng EYL, et al.. Ethnic-specific effects of the LILRB2-LILRB5 locus and newly identified risk loci for Alzheimer's disease in the East Asian population. Alzheimers Dement 2026;22(2):e71219. DOI 10.1002/alz.71219.

63. Park JC, Han SH, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review. BMB Rep 2020;53(1):10-19. DOI 10.5483/BMBRep.2020.53.1.309.

64. Swift IJ, Sogorb-Esteve A, Heller C, Synofzik M, Otto M, Graff C, et al.. Fluid biomarkers in frontotemporal dementia: past, present and future. J Neurol Neurosurg Psychiatry 2021;92(2):204-215. DOI 10.1136/jnnp-2020-323520.

65. TREM2 and microglial immunity in Alzheimer's disease: mechanisms, genetics, and therapeutic opportunities - Frontiers, accessed March 23, 2026, DOI 10.3389/fimmu.2026.1739875">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1739875

66. Technology - LILRB2 Monoclonal Antibody for Therapeutic and Diagnostic Uses of Neurodegenerative Diseases, accessed March 23, 2026, https://uthealth.technologypublisher.com/technology/55342

67. Che Y, Yu Z, Ji S, Yang D. Decoding TREM2 Signaling Pathways. Neurology Neuroimmunology & Neuroinflammation 2026;13(2). DOI 10.1212/NXI.0000000000200527.

68. Zhao P, Xu Y, Jiang LL, Fan X, Ku Z, Li L, et al.. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol Neurodegener 2022;17(1):44. DOI 10.1186/s13024-022-00550-y.

69. Hou J, Chen Y, Cai Z, Heo GS, Yuede CM, Wang Z, et al.. Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model. Sci Transl Med 2024;16(741):eadj9052. DOI 10.1126/scitranslmed.adj9052.

70. Increased CD33 levels tune activation and function of induced human microglial cells through inhibition of the TREM2 pathway - bioRxiv, accessed March 23, 2026, DOI 10.64898/2026.01.28.701050">https://www.biorxiv.org/content/10.64898/2026.01.28.701050

71. Wang T, Liu X, Wang X, Hua F, Yan L. TREM2 and microglial immunity in Alzheimer's disease: mechanisms, genetics, and therapeutic opportunities. Front Immunol 2026;17:1739875. DOI 10.3389/fimmu.2026.1739875.

72. New Trials, New Targets: New Hope for Alzheimer's - Medscape, accessed March 23, 2026, https://www.medscape.com/viewarticle/new-trials-new-targets-new-hope-alzheimers-2025a1000hob